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abstract
PURPOSE The COVID-19 pandemic has affected healthcare systems globally, leading to reorganization of
medical activities. We performed an international survey aimed to investigate themedium- and long-term impact
on oncology units.
MATERIALS AND METHODS An 82-item survey was distributed from June 17 to July 14, 2020 among medical
oncologists worldwide.
RESULTSOne hundred ninemedical oncologists from 18 countries in Europe (n = 93), United States (n = 5), and
Latin America (n = 11) answered the survey. A systematic tracing of COVID-19–positive patients was continued
in the postacute phase by 77.1% of the centers; 64.2% of the respondents participated in a local registry and
56% in international or national registries of infected patients. Treatment adaptations were introduced, and
surgery was the most affected modality being delayed or canceled in more than 10% of patients in 34% of the
centers, whereas early cessation of palliative treatment was reported in 32.1% of the centers; 64.2% of re-
spondents reported paying attention to avoid undertreatments. The use of telemedicine has been largely in-
creased. Similarly, virtual tools are increasingly used particularly for medical education and international or
national or multidisciplinary meetings. 60.6% of the participants reduced clinical activity, and 28.4% com-
pensated by increasing their research activity. Significant reduction of clinical trial activities is expected in 37%
of centers this year. The well-being of healthcare staff would not recover by the end of the year according to 18%
of the participants.
CONCLUSION The COVID-19 outbreak has had a major impact on oncologic activity, which will persist in the
future, irrespective of geographical areas.
JCO Global Oncol 7:162-172. © 2021 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Since late 2019, a new coronavirus disease (COVID-
19), caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has been spreading
worldwide and was declared as a pandemic on March
11, 2020.1,2
The symptomatologic profile of COVID-19 is highly
variable, from asymptomatic cases to severe syn-
dromes, characterized by respiratory failure and organ
injury.3,4 Recognized risk factors for severe symp-
tomatology by SARS-CoV-2 infection are older age;
male sex; poor performance status; and presence of
comorbidities such as underlying pulmonary disease,
cardiovascular disease, diabetes, and cancer.5–7 For
patients with cancer, susceptibility to infection and the
characteristics of COVID-19 vary depending on tumor
type, stage of disease, and active treatments, with a
higher risk of infection, complications, and case fatality
for hematologic and lung malignancies.6,8–11 Consid-
ering this specific high-risk, emergency measures to
control the spread of the infection were implemented
at the peak of the pandemic.12 These included the use
of treatment regimens with longer intervals, a prefer-
ence for oral treatments instead of intravenous, the
earlier discontinuation of palliative treatments, the use
of hypofractionated radiotherapy instead of standard-
course radiotherapy, and the expanded use of
telemedicine.13 All these measures were principally
based on expert opinions, in the absence of strong
scientific evidence.14 In addition to oncologic care,
other areas have been impacted by the COVID-19
pandemic, such as medical education, scientific ac-
tivity, and the well-being of both patients and
healthcare staff.15–17 These changes are likely to have
short- and long-term impact.
With the purpose to analyze the impact on oncologic
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activity, medical education, and the well-being of health-
care workers, we performed this survey with broad rep-
resentation from several countries.
MATERIALS AND METHODS
An anonymous online questionnaire (Data Supplement)
was sent by e-mail and shared through online platforms to
oncologists (both specialists and in training) on June 17,
2020. The last answer was recorded on July 14. The
majority of answers were mandatory, with the exception of
questions regarding personal and psychologic well-being
during the COVID-19 pandemic and questions on breast
cancer care.
Study Objectives
The current survey aimed at investigating the measures
adopted to manage the COVID-19 outbreak in oncology
departments, the measures implemented to reorganize
clinical, research, and educational activities, and the short-
and long-term impact of the pandemic on oncologic care,
scientific activity, and well-being of healthcare workers.
Characteristics of the Survey
This survey was designed by a working group of medical
oncologists (n = 20) involved in clinical and research ac-
tivities in different areas. It was composed of 82 questions,
which were divided into different sections: (1) demo-
graphic, medical training, and employment information of
respondents (questions 1-9); (2) experience with COVID-19
in the oncology departments and preventive measures
adopted (questions 10-20); (3) data collection of COVID-19
and outcome of patients with cancer who developed
COVID-19 disease (questions 21-22); (4) COVID-19 impact
on oncologic treatments in general, with a focus on breast
cancer (questions 23-37); (5) teleconsultations (questions
38-48); (6) activity in oncology departments (questions 49-
51); (7) virtual meetings (questions 52-65); (8) clinical
activity and scientific production during COVID-19 crisis
(questions 66-71); (9) COVID-19 and psychologic impact
(questions 72-78); and (10) COVID-19 and clinical trials
(questions 79-82).
Statistical Analysis
Considering the descriptive nature of the study, no sample
size calculation was preplanned. We estimated a target
population of survey recipients to be approximately 400
oncologists. With an expected margin of error of 8% with a
95% confidence level, 100 respondents would be needed.
Analyses were mainly descriptive. To explore differences in
categorical variables in answers collected regarding the
same issue during the acute phase and the postacute
phase of the COVID-19 infection course, a McNemar test
was applied. A Fisher’s exact test was applied to evaluate
categorical variables. Descriptive analyses were conducted
to investigate potential differences in the answers provided
by oncologists working in Europe compared with those
working in the United States and Latin America. Tests were
two-sided, and P , .05 was considered statistically
significant.
RESULTS
The 82-item survey was distributed by 20 medical oncol-
ogists from ten of the most affected countries during the
period June 17 to July 14, 2020. A total of 109 physicians
from 18 countries filled out the survey. The median age of
participants was 48.5 years (interquartile range, 38 to
55.8), with a median of 20 years (interquartile range, 10.5
to 25) working in oncology including residency; the majority
were male (61.5%). Sixty-eight participants (62.4%)
worked in academic hospitals, 32 (29.6%) in community
hospitals, and five (4.6%) in private centers without
overnight ward. The place of work was in most cases a
general hospital with oncology unit (n = 72, 66.1%) or a
cancer center (n = 35, 32.1%). The main oncology sub-
specialization was breast cancer for the majority (60.6%).
Table 1 summarizes respondents’ characteristics.
During the survey, the participating countries had different
infection loads, with an incidence risk ranging from 8.7 new
cases/100,000 inhabitants in Italy to 383.4/100,000 in the
United States (Table 2).18,19 In seven countries (Austria,
Belgium, France, Germany, Italy, the Netherlands, and
CONTEXT
Key Objective
The COVID-19 outbreak has had a significant and bursting influence on oncology units; how will this change oncologic care
organization in the near future?
Knowledge Generated
The emergence of the pandemic has led to treatment adaptations, with surgery being the most affected modality, followed by
chemotherapy and radiotherapy. Moreover, the health emergency has led to an increase in the use of telemedicine and
virtual meetings and to the reduction of clinical trial activities.
Relevance
Many of the changes introduced in oncology to cope with the pandemic have a greater impact on the treatment of patients and
the well-being of healthcare staff, and some of these will persist in the future, particularly all telemedicine activities.
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Spain) the survey was completed after the first peak
(n = 86), in four countries (Luxembourg, Sweden, Switzerland,
and United States) during a resurgence of the pandemic
(n = 12), and in seven countries (Argentina, Brazil,
Ecuador, Mexico, Paraguay, Peru, and Venezuela) at the
beginning of the outbreak (n = 11).
Experience With COVID-19 and Data Collection
Figure 1A summarizes the cumulative number of patients
diagnosed with COVID-19 at each site at the time of survey
completion. At the peak of the pandemic, 80.7% of the
centers organized a systematic tracing of infected patients,
and 77.1% extended the systematic tracing in the post-
acute phase (P = .125) (Fig 1B). A local registry of infected
patients was organized in 64.2% of the cases, and 56% of
the respondents participated in an international or national
registry (Fig 1C). No significant differences were observed
between Europe, United States, and Latin America.
Monitoring of COVID-19 Infection
A triage for COVID-19 infection was done with nasal or
throat swab or gargle test before admission to day care unit
and to overnight stay and before starting a new treatment in
32.1%, 62.4%, and 27.5% of the participants’ centers
during the peak of the pandemic and in 27.5%, 58.7%,
and 30.3% in the postacute phase, respectively. The dif-
ferences between the use of nasal or throat swab or gargle
test as the triage method during and after the peak of the
pandemic were not significant (P value for day care unit,
overnight stay ward, and new treatment of .06, .12, and .25,
respectively); no significant differences were observed by
geographic area as well.
Serologic tests were performed before initiating a new
systemic anticancer therapy in only 7.3% of the cases as
routine and in 12.8% as part of research. Interestingly, the
use of serologic test before starting a new treatment was
significantly higher in Latin America (36.4%) compared
with Europe (4.3%) and the United States (0%), although
small sample size limits this analysis.
COVID-19 Impact on Oncologic Treatment
The majority (64.2%) of respondents agreed that the most
important risk for oncology patients is undertreatment by
stopping or adapting the therapy, rather than the risk of
dying from COVID-19.
Surgery was the most affected therapy being canceled or
delayed in more than 10% of patients in 34% of the
centers, followed by chemotherapy in 22%, radiotherapy in
13.7%, immunotherapy in 9.1%, antibody treatment in
9%, and oral targeted therapy in 3.7% (Fig 2A). However,
15.7% of the respondents reported earlier progression to
surgery in patients receiving neoadjuvant therapy (. 10%,
Fig 2B), whereas 27.6% noted increased use of neo-
adjuvant systemic therapy instead of primary surgery in
more than 10% of patients. Regarding radiotherapy,
standard fraction treatment was more frequently affected
TABLE 1. Respondents’ Characteristics
Respondents’ Characteristics No. (%)
Age, median (IQR) 48.5 (38 to 55.75)
Years worked in oncology (including residency),
median (IQR)





Academic hospital 68 (62.4)
Community hospital 32 (29.6)
Private center without overnight stay 5 (4.6)
Other 4 (3.7)
Type of oncologic center
General hospital with oncology unit 72 (66.1)
Specialized separate anticancer center 35 (32.1)
Private office 1 (0.9)
Other 1 (0.9)
Main specialization
Breast cancer 66 (60.6)
Lung cancer 9 (8.3)
GI cancer 11 (10.1)
Gynecologic cancer 3 (2.7)
Skin cancer 3 (2.7)
Urogenital cancer 10 (9.2)



















United States 5 (4.6)
Venezuela 1 (0.9)
Abbreviation: IQR, interquartile range.
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than stereotactic radiotherapy, with a rate of cancellation or
delay in more than 10% of patients by 13.7% and 8.3% of
the centers, respectively. Conversely, 42.2% of the par-
ticipants did not report delay or discontinuation of oral
targeted therapy. Therapies not affected were immuno-
therapy in 40.4% of the participants’ centers, monoclonal
antibody treatment in 39.4%, stereotactic radiotherapy in
38.5%, standard fraction radiotherapy in 27.7%, chemo-
therapy in 19.3%, and surgery in 12.8%.
In breast cancer (89 respondents), the most affected
treatment was everolimus, which was estimated to be
permanently stopped or delayed in more than 10% of
patients by 15%, followed by CDK4/6 inhibitors by 8.9%
and alpelisib by 6.7% of respondents.
A switch from intravenous to subcutaneous or oral for-
mulation was reported in more than 10% of patients by
15.6% of the participants (Fig 2B). To reduce hospital
admissions, an increased use of home administration was
reported by 51.6% of the participants. Overall, 18.3% of the
participants stated that their center already performed
home deliveries before the COVID-19 outbreak, which in-
creased to 45% during the peak of the pandemic and to
34.9% in the postacute phase.
Treatment adaptations were introduced, including a
change of schedule or regimen in more than 10% of pa-
tients by 39.5% of the respondents to the survey, post-
ponement of immunotherapy for stable patients by 21%,
and the decreased use of double immunotherapy by 11.1%
(Fig 3B). In addition, modification of concomitant treat-
ments was considered, such as decreased use of corti-
costeroids and increased use of granulocyte colony-
stimulating factor (G-CSF) and erythropoietin in more than
10% of patients, respectively, by 21.9%, 34.8%, and 6.4%
of the survey respondents (Fig 2B).
An early switch to best supportive care was also reported. In
particular, 77.1% of the participants noted early cessation
of systemic treatment in at least one patient and 32.1% in
more than 10% of patients (Fig 2B).
Decreased oncology unit hospitalizations and use of
emergency units was observed in at least one patient by
81.6% and 81.7% of the participants, respectively, and in
more than 10% of patients by 44.9% and 52.3%.
At the time of the survey, most participants (73.4%) stated
that treatment choice was no longer influenced by COVID-
19. A significant difference was found by geographical
area, with 78.5% of the European respondents stating that
treatment choice was no longer influenced by COVID-19
versus 40% in the United States and 54.5% in Latin
America (P = .01), reflecting the difference in the severity of
the pandemic at the moment of survey completion.
Activity of Oncology Departments
The activity of oncology clinics during the COVID-19 crisis
significantly decreased compared with that prior to the
TABLE 2. Incidence Risk During the Period June 17-July 14, 2020 in the Countries Participating in the Survey
Country No. of New Casesa Inhabitantsb
Incidence Risk
(per 100,000 Inhabitants)
Argentina 71,358 45,196,000 157.89/100,000
Austria 1,818 9,006,000 20.19/100,000
Belgium 2,537 11,590,000 21.89/100,000
Brazil 241,623 212,559,000 113.67/100,000
Ecuador 21,080 17,643,000 119.48/100,000
France 14,207 65,274,000 21.77/100,000
Germany 11,852 83,784,000 14.15/100,000
Italy 5,516 60,462,000 8.97/100,000
Luxembourg 971 626,000 155.11/100,000
Mexico 151,693 128,933,000 111.65/100,000
The Netherlands 1,950 17,135,000 11.38/100,000
Paraguay 1,766 7,133,000 24.76/100,000
Peru 92,959 32,970,000 281.95/100,000
Spain 11,936 46,755,000 25.53/100,000
Sweden 18,178 10,099,000 180/100,000
Switzerland 1,829 8,655,000 21.13/100,000
The United States 1,269,000 331,003,000 383.38/100,000
Venezuela 6,624 28,436,000 23.3/100,000
aData from https://github.com/CSSEGISandData/COVID-19.
bData from https://population.un.org/wpp/Download/Standard/Population/.
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pandemic. Particularly, 69.7% of the participants stated
that the number of consultations decreased, whereas
working days increased in length according to 45.9% of the
participants, because of the prolongation of each visit.
The activity load in June-July 2020 was reduced in terms of
admissions to the overnight stay ward, admissions to the
day care unit, outpatient consultations, and the number of
new cases compared with the overall experience before the
COVID-19 crisis in 71.6%, 64.2%, 68.9%, and 71.6% of
the respondents’ centers (Fig 3A). The margin for im-
provement in the clinical activity load expected by the end
of 2020 was minimal. In fact, a decrease in admissions to
the overnight stay ward, admissions to the day care unit,
outpatient consultations, and the number of new cases
were expected by 66.9%, 60.6%, 65.2%, and 64.2% of the
respondents to the survey (Fig 3B).
Teleconsultations and Virtual Meetings
During the pandemic peak, a considerable increase in the
use of telemedicine was observed. Teleconsultations by
video or phone instead of on-site consultations were done
for more than 20% of patients by 81.7% of the participants,
compared with only 21.1% of the participants in the
postacute phase (P , .0001) (Figs 4A and 4B). 16.5% of
the physicians responding to the survey will not organize a
new outpatient consultation for each visit managed by
phone or video call during the COVID-19 crisis. Themajority
of the participants (81.7%) stated that they will continue to
use telemedicine more in the future than in the past (Fig
4C).
During the pandemic peak, teleconsultations were done for
patients in long-term follow-up (94.5%), for patients re-
ceiving oral drugs (92.7%), for patients receiving immuno-
therapy (57.8%), and for patients receiving chemotherapy
(55%).
Nevertheless, regulatory issues still persist, without reim-
bursement for teleconsultations in 30.3% of the partici-
pating centers. Many regulatory barriers have been
temporarily removed to accelerate the use of telehealth
services during the pandemic; reimbursement for tele-
consultations increased from 33% before COVID-19 to
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FIG 1. Experience with COVID-19 and data collection. (A) The number of cases diagnosed with COVID-19 in the participants’ centers in the day care unit
and in the overnight stay ward. Answers concerning systematic tracing and participation in local or national or international registry (B and C, respectively).
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reduction in fees compared with on-site consultation in
about a quarter of the cases. Interestingly, an increase in
reimbursement for telemedicine was reported only in
Europe (from 29% to 69.9%, P, .0001) and in the United
States (from 60% to 100%, P = .250), whereas in Latin
America, teleconsultations were even reimbursed before
the COVID-19 pandemic in 54.5% and the frequency of
reimbursement remains unchanged.
To reduce interpersonal contacts, most meetings are
taking place virtually. Virtual meetings were a good al-
ternative to live meetings for multidisciplinary team for
61.5% of the medical oncologists, for administrative and/
or strategic meetings for 63.3%, for continued medical
education for 66.9%, for personal scientific discussions
for 61.4%, for teaching for 43.2%, for international
meetings for 33.9%, and for networking with industry and
academic colleagues for 44.1%. Continued use of virtual
meetings in all fields was expected by more than 80% of
the participants.
Scientific Activity and Clinical Trials
Although 60.6% of the participants reduced their clinical
activity at the peak of the pandemic, 48.6% were unable to
use the time saved for scientific activities because of the
consequences of COVID-19 and the increased burden of
organizing patient care. Only 28.4% of the participants
reported an increase in scientific activity.
Laboratory activities were also interrupted during the peak
of the pandemic according to 55.9% of the participants,
and only 34% stated that laboratory activities had now
resumed to the same level as before COVID-19.
Overall, 60.6% of the participants observed a reduction in
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Oral Therapy
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Decreased Use of Double Immunotherapy
Postponed Administration of Immunotherapy
for Stable Patients
Change of Schedule or Regimen
FIG 2. Treatment modalities affected
by COVID-19 pandemic. (A) The
treatment modalities affected by
COVID-19 pandemic are summa-
rized. (B) The types of modifications
of treatment modalities are shown in
detail. In both the figures, the per-
centages represent the rate of
changes observed in more than 10%
of the patients by the respondents to
the survey. EPO, erytropoietin; G-CSF,
granulocyte colony-stimulating factor.
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recommended by many regulatory authorities. For those
clinical trials that continued, an increase in major protocol
deviations was observed by 27.5% of the participants.
Currently, clinical trial activities are open or will be reac-
tivated in the near future according to 72.5% of the par-
ticipants, in particular according to 76.3% of respondents
from Europe, 40% from the United States, and 45.5% from
Latin America (P = .07). A significant reduction in clinical
trial activities is expected by the year end by 36.7% of the
participants and 35.8% expect severe financial problems
for their clinical trial unit.
Psychologic Impact of COVID-19 Outbreak
The well-being of medical oncologists was explored by this
survey with optional questions, answered by 108 (99.1%)
participants. Overall, 50% stated that their general well-
being was largely impacted at the peak of the pandemic; it
is still impacted in the postacute phase in 29% and 18%
expect not to recover to baseline by the end of the year.
Psychologic support for caregivers was organized by the
institution of 62.7% of the participants, but only 10.3%
have asked or have intention to ask for this service.
DISCUSSION
The impact of COVID-19 on almost all medical activities has
been widely documented and discussed. This includes
outcome in patients with solid and hematologic cancers
who become infected by SARS-CoV-2, modifications in
oncologists’ attitudes and decision making, and reorgani-
zation of oncologic care and facilities to reduce the risk for
inhospital contagion and virus spread.12,13,15,20,21 What is
more difficult to assess are the indirect consequences of
the COVID-19 pandemic with regard to oncology, such as
the reduced number of new cancer diagnoses during the
acute phase of the epidemic because of the delay or in-
terruption of cancer screening procedures.22,23 The pro-
jections about an expected cumulative excess of avoidable
cancer deaths within the next years can only be estimated
by modeling studies.24,25 To allow for a comprehensive
overview on this subject, our survey aimed at investigating,
to our knowledge, for the first time, the expected medium-
and long-term burden of the COVID-19 pandemic on on-
cology, through the direct report of representatives from
oncology departments throughout Europe, the United
States, and Latin America. Our survey confirms that COVID-
19 has had a major impact on organization of patient care,
well-being of caregivers, continued medical education, and
clinical trial activities in oncology.
A systematic monitoring of the COVID-19 dynamics using
nasal or throat swab or gargle test will be continued in the
majority of centers, especially as a triage procedure before
overnight hospitalization or surgery, reflecting an expected
continuation of the pandemic in the near future. Of course,
anticancer treatments have been readapted as suggested
by various scientific societies and international guidelines,
especially those that put the patient in a condition of greater
immunodepression and/or have overlapping side effects
with COVID-19 symptoms, albeit 64.2% of respondents
agree or strongly agree that undertreatment is the most
important risk for patients with cancer. This is in agreement
with a recent study that showed similar COVID-19–related
mortality rates and complications in patients with or without
cancer, cautioning about possible consequences of
treatment limitation in patients with cancer.26 From our
survey emerged that surgery was the treatment modality
most affected by COVID-19–related changes. Sud et al27
estimated that more than 4,700 deaths/year in England
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FIG 3. Reduction of activity in oncology departments because of COVID-19 outbreak. Magnitude of the reduction of activity in oncology departments in
June-July 2020 (A) and the expected reduction at the end of 2020. The percentages showed represent the proportion of participants in the survey.
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different cancers with stage 1-3 (with differences according
to the tumor type). A systematic review revealed moderate
evidence that a delayed surgical approach to GI malig-
nancies can lead to a worse outcome, whereas another
study did not show such a relationship for prostate
cancers.28,29 The risks of tumor progression by delaying
radical surgery should be evaluated on a case-by-case
basis. In some diseases, such as luminal early breast
cancer, simple clinical algorithms can help to delay sur-
geries without compromising patient outcome.30
Regarding systemic oncologic adaptation, it is worthy of
consideration that 34.6% of respondents increased the use
of G-CSF during the COVID-19 pandemic. Both the ad-
ministration and inhibition of G-CSF are currently being
under evaluation as therapeutic options for treating COVID-
19 manifestations, thus its wide prophylactic use cannot be
suggested lightly.31
Approximately 82% of participants estimate that they will
continue to use telemedicine, and it is encouraging to find
that coverage of its cost goes in parallel with the increase in
its use.
Although the oncologic healthcare workforce hopes for a
rapid normalization of professional activities after the
lockdown, a long-term impact of COVID-19 is expected.
Thus, the risk of delayed diagnosis of new cancers and
economic consequences of COVID-19 on access to health
care and cancer treatments have to be carefully evaluated.
It is of concern that the need to obtain new scientific ev-
idence to guide clinical practice in the next months may be
hindered by reduced clinical trial and laboratory activities,
although research activities seem to be recovering.
Moreover, the rapid spread of COVID-19 epidemics is
associated with psychologic impact on oncology patients,
compounded by multiple factors: knowledge that the in-
dividual is at higher risk of serious complication if infected
by COVID-19, loneliness and isolation as a result of social
distancing, and the underlying constant fear of the cancer.
The results of our international survey reflect the current
status in international oncology but need to be interpreted
with caution because of some intrinsic limitations. As stated
above, the results are influenced by two main variables:
1. The epidemiology of COVID-19 infections in each
country, in terms of the number of cases or inhabitants
and timeline of the epidemic.
2. the strategies adopted by that country to face the
pandemic.
To overcome these limitations, we have provided sub-
analyses according to geographical areas. We grouped
European countries together since almost all had , 30
COVID-19 cases/100,000 inhabitants at the time of the
interview and were experiencing the first postpeak phase of
the epidemic. For differences in the resources to cope with
the epidemic, we did not consider United States and Latin
America together, although some countries had similar
contagion dynamics.
There are still many challenges ahead in the fight against
COVID-19, with many unanswered questions facing prac-
ticing oncologists on a daily basis. Reflecting on real-world
experience with data collected in the large registries that
have been created will also help us extrapolate and de-
termine which is the best evidence to be used in managing
future cases of COVID-19 outbreaks or other pandemics.
Differences in the prevalence of COVID-19 cases, clinical
settings, staffing, and access to resources will result in
varying adoption of many of these recommendations.
Collective wisdom and experience from different organi-
zations, communities, and governments will help shape
the best approach to control the pandemic at a global
level.
To conclude, the adaptations to a changed daily working
life reflect the plasticity of oncology, in its nature ac-
customed to renewing itself to follow the continuous
changes led by clinical research. It is important to
deepen the understanding of indirect effects of the
COVID-19 pandemic on organizational issues and the
cost-effectiveness of diagnostic and treatment options,
which can be more difficult to weigh but more crushing in
the long run.
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FIG 4. Teleconsultations during and after COVID-19 outbreak. The use of teleconsultations in oncology department during the peak of the pandemic (A) and
in the postacute phase (B). (C) Representation of the expected use of telemedicine in the near future after COVID-19 crisis.
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Oncol 31:S1010, 2020
18. United Nations. Population Division. Department of Economics and Social Affairs: World Population Prospects 2019. New York, NY, United Nations, 2019
19. COVID-19 data repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. https://github.com/CSSEGISandData/
COVID-19
20. Tagliamento M, Spagnolo F, Poggio F, et al: Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. Eur J Clin Invest
50:e13315, 2020
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